St Jude Medical launches Optis mobile system in Japan and Europe


St. Jude Medical has announced the launch of the company’s Optis mobile system in Japan and Europe. The diagnostic system is designed to couple optical coherence tomography (OCT) and angiography co-registration with fractional flow reserve (FFR) technology into one portable system for hospitals with multiple catheterisation labs.

The latest Optis system is designed to offer physicians an efficient way to optimise percutaneous coronary intervention (PCI) procedures for the treatment of vascular disease by combining diagnostic tools designed to improve patient outcomes into one portable device.

Utilising a combination of technology available in the St. Jude Medical Optis integrated system, the Optis mobile system is designed to help physicians make improved stenting decisions based on high-resolution and three dimensional OCT views of coronary anatomy while simultaneously mapping their exact location via angiogram. The Optis mobile system also integrates St. Jude Medical PressureWire FFR measurement technology, which is designed to offer physicians detailed coronary haemodynamic information during PCI. Clinical data has shown the physiological measurements provided by St. Jude Medical FFR technology can improve outcomes and reduce health care costs over traditional diagnostic imaging tools, according to a company release.

“As the interventional cardiology landscape continues to expand, there is a real need for more portable intravascular imaging systems to ensure hospitals with multiple catheterisation labs have the right technology available for physicians to make more informed treatment decisions during PCI,” says Nick West, Papworth Hospital, Cambridge, UK. “The imaging advancements offered with the Optis Mobile System provide the same benefits of the Optis Integrated System, and allow physicians to clearly visualise complex cardiac anatomy and evaluate how to best proceed during PCI.”

St. Jude Medical’s Ilumien System combines OCT and FFR technology with the aim of enabling a more detailed physiological and anatomical analysis of blood flow blockages inside the coronary vessels.

Eric Fain, group president of St. Jude Medical, says, “In contrast with intravascular ultrasound, OCT offers increased resolution and highly-detailed intracoronary arterial views, which can improve PCI procedures, especially in complex cases.”

The benefits of utilising OCT and FFR during PCI are supported by a robust portfolio of clinical data, according to St. Jude Medical. The Ilumien I and Ilumien II studies have shown that the company’s OCT imaging technology can influence pre- and post-PCI decision making, stent sizing and deployment. The St. Jude Medical-sponsored FAME body of evidence demonstrates that the company’s PressureWire FFR measurement technology can improve patient outcomes and reduce costs in patients with stable coronary artery disease, according to a company release.

The multicentre ILUMIEN III: OPTIMIZE PCI clinical trial is currently underway. It will develop the body of clinical evidence supporting OCT technology in relation to first generation imaging tools, according to a St. Jude Medical release.